Literature DB >> 1444311

Effects of the aggregation state of amphotericin B on its toxicity to mice.

J Barwicz1, S Christian, I Gruda.   

Abstract

Amphotericin B (AmB) is a very effective antifungal agent for most systemic fungal infections. However, the relatively high toxicity of this drug imposes limits on its clinical usefulness. Most of the current work in this field is devoted to the search for less-toxic formulations of the drug. Here we describe the effects of three surfactants, one anionic and the other two nonionic, on the aggregation state of AmB in solutions which were injected intravenously into mice. The degree of aggregation of AmB was monitored spectroscopically and by light scattering. The toxicity was expressed as percentage of survivors. These results were compared with those obtained with doses of AmB the same as those present in a commercial formulation of AmB, Fungizone. Two surfactants, lauryl sucrose and sodium deoxycholate, used at concentrations which induced monomerization of AmB, substantially decreased the acute toxicity of AmB to mice. Conversely, the third surfactant, Tween 80, showed a synergistic potentiation of the toxicity of the antibiotic. A good correlation was found between the in vivo toxicity and the aggregation state of AmB in injected solutions. Solutions in which AmB was almost entirely monomeric were half as toxic after 24 h and about six times less toxic after 1 week than the corresponding solutions of Fungizone.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1444311      PMCID: PMC245494          DOI: 10.1128/AAC.36.10.2310

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  15 in total

Review 1.  Lipid emulsions as drug delivery systems.

Authors:  S S Davis; C Washington; P West; L Illum; G Liversidge; L Sternson; R Kirsh
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

2.  The influence of Myrj 59 on the solubility, toxicity and activity of amphotericin B.

Authors:  C Tasset; V Préat; M Roland
Journal:  J Pharm Pharmacol       Date:  1991-05       Impact factor: 3.765

3.  One-sided action of amphotericin B on cholesterol-containing membranes is determined by its self-association in the medium.

Authors:  J Bolard; P Legrand; F Heitz; B Cybulska
Journal:  Biochemistry       Date:  1991-06-11       Impact factor: 3.162

4.  Inhibition of the interaction between lipoproteins and amphotericin B by some delivery systems.

Authors:  J Barwicz; R Gareau; A Audet; A Morisset; J Villiard; I Gruda
Journal:  Biochem Biophys Res Commun       Date:  1991-12-16       Impact factor: 3.575

5.  Treatment of murine candidosis and cryptococcosis with a unilamellar liposomal amphotericin B formulation (AmBisome).

Authors:  J P Adler-Moore; S M Chiang; A Satorius; D Guerra; B McAndrews; E J McManus; R T Proffitt
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

6.  Liposomal amphotericin B (AmBisome) in the treatment of fungal infections in neutropenic patients.

Authors:  R Chopra; S Blair; J Strang; P Cervi; K G Patterson; A H Goldstone
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

7.  Liposomal amphotericin B (AmBisome): safety data from a phase II/III clinical trial.

Authors:  F Meunier; H G Prentice; O Ringdén
Journal:  J Antimicrob Chemother       Date:  1991-10       Impact factor: 5.790

8.  Treatment of hepatosplenic candidiasis with liposomal-amphotericin B.

Authors:  G Lopez-Berestein; G P Bodey; L S Frankel; K Mehta
Journal:  J Clin Oncol       Date:  1987-02       Impact factor: 44.544

9.  Mechanism of the selective toxicity of amphotericin B incorporated into liposomes.

Authors:  R L Juliano; C W Grant; K R Barber; M A Kalp
Journal:  Mol Pharmacol       Date:  1987-01       Impact factor: 4.436

10.  Effect of lipid composition and liposome size on toxicity and in vitro fungicidal activity of liposome-intercalated amphotericin B.

Authors:  F C Szoka; D Milholland; M Barza
Journal:  Antimicrob Agents Chemother       Date:  1987-03       Impact factor: 5.191

View more
  34 in total

1.  Synthesis of a highly water-soluble derivative of amphotericin B with attenuated proinflammatory activity.

Authors:  Samusi A Adediran; Timothy P Day; Diptesh Sil; Matthew R Kimbrell; Hemamali J Warshakoon; Subbalakshmi S Malladi; Sunil A David
Journal:  Mol Pharm       Date:  2009 Sep-Oct       Impact factor: 4.939

2.  Heat-induced superaggregation of amphotericin B reduces its in vitro toxicity: a new way to improve its therapeutic index.

Authors:  F Gaboriau; M Chéron; C Petit; J Bolard
Journal:  Antimicrob Agents Chemother       Date:  1997-11       Impact factor: 5.191

Review 3.  Structural insights on biologically relevant cationic membranes by ESR spectroscopy.

Authors:  Julio H K Rozenfeld; Evandro L Duarte; Tiago R Oliveira; M Teresa Lamy
Journal:  Biophys Rev       Date:  2017-08-23

4.  Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis.

Authors:  Aiman Abu Ammar; Abed Nasereddin; Suheir Ereqat; Mary Dan-Goor; Charles L Jaffe; Eyal Zussman; Ziad Abdeen
Journal:  Drug Deliv Transl Res       Date:  2019-02       Impact factor: 4.617

5.  Reformulation of Fungizone by PEG-DSPE Micelles: Deaggregation and Detoxification of Amphotericin B.

Authors:  Celeste Alvarez; Dae Hwan Shin; Glen S Kwon
Journal:  Pharm Res       Date:  2016-05-19       Impact factor: 4.200

6.  Treatment of experimental visceral leishmaniasis with amphotericin B in stable albumin microspheres.

Authors:  J A Sánchez-Brunete; M A Dea; S Rama; F Bolás; J M Alunda; R Raposo; M T Méndez; S Torrado-Santiago; J J Torrado
Journal:  Antimicrob Agents Chemother       Date:  2004-09       Impact factor: 5.191

7.  In vitro renal toxicity and in vivo therapeutic efficacy in experimental murine cryptococcosis of amphotericin B (Fungizone) associated with Intralipid.

Authors:  V Joly; R Farinotti; L Saint-Julien; M Chéron; C Carbon; P Yeni
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

8.  Treatment of murine candidiasis and cryptococcosis with amphotericin B incorporated into egg lecithin-bile salt mixed micelles.

Authors:  J Brajtburg; S Elberg; S J Travis; G S Kobayashi
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

9.  Amphotericin B incorporated into egg lecithin-bile salt mixed micelles: molecular and cellular aspects relevant to therapeutic efficacy in experimental mycoses.

Authors:  J Brajtburg; S Elberg; G S Kobayashi; J Bolard
Journal:  Antimicrob Agents Chemother       Date:  1994-02       Impact factor: 5.191

10.  Injectable in situ cross-linking hydrogels for local antifungal therapy.

Authors:  Sarah P Hudson; Robert Langer; Gerald R Fink; Daniel S Kohane
Journal:  Biomaterials       Date:  2009-11-26       Impact factor: 12.479

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.